林鸽教授 – 生物醫學學院

林鸽教授

Research Professor

B.Sc., M.Sc., Ph.D.

39436824

linge@cuhk.edu.hk

505A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

Publons

ORCID

个人简介

Prof. LIN Ge (林鸽) is currently working as a full professor at School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK). She also serves as Director of Joint Research Laboratory for Promoting Globalization of Traditional Chinese Medicines between Shanghai Institute of Materia Medica, Chinese Academy of Sciences and CUHK. Prof. Lin has a longstanding interest in pharmaceutical research including: 1) drug metabolism (DM) and pharmacokinetics (PK); 2) pharmacology and mechanisms of drug actions; 3) idiosyncratic adverse effect/toxicity; 4) herb-drug interactions; and 5) globalization of Chinese medicinal (CM) herbs. She is an expert in applying multidisciplinary studies for investigating TCM herbs. Her research in CM herbs integrates chemical analysis, PK, PD, and toxicology studies for the identification of bioactive ingredients with confirmed bioavailability and verified PK fates, safety assessment, and development of quality control of CM herbs and their beneficial interactions with orthodox drugs. Prof. Lin is also working on translational research. One of her on-going research projects is to develop biomarkers for the diagnosis and assessment of hepatotoxicity induced by pyrrolizidine alkaloids (PA)-containing herbs and PA-contaminated foods. Her team is one of the world leading groups in this field and has been well recognized internationally.

Research Interests

Toxicology, in particular idiosyncratic hepatotoxicity and tumorigenicity.
Herb-drug interactions, in particular chemopreventive and synergistic anticancer effects of CM herbs in the combinational therapy of anticancer drugs with CM herbs.
Pharmacokinetics of therapeutic drugs and CM herbs.
Integrative approach for the study of CM herbs, including chemical analysis, pharmacology, pharmacokinetics, safety and quality control of CM herbs.

Selected Publications

Ma, J., Zhang, C., He, Y., Chen, X. & Lin, G.* (2022). Fasting augments pyrrolizidine alkaloid-induced hepatotoxicity. Archives of Toxicology. 96, 639-651.
He, Y., Shi, M., Wu, X., Ma, J., Ng, K.T., Xia, Q., Zhu, L., Fu, P.P., Man, K., Tsui, S.K. & Lin G.* (2021). Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology. 74, 264-280.
He, Y., Ma, J., Fan, X., Ding, L., Ding. X., Zhang, Q.** & Lin, G.** (2021). The key role of gut-liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity. Acata Pharmaceutical Sinica B. 11, 3820-3835.
He, Y., Long, Y., Zhang, C., Ma, J., Ke, C., Tang, C., Ye, Y. & Lin, G.* (2021). Dietary alcohol exacerbates the hepatotoxicity induced by pyrrolizidine alkaloids: Hazard from food contamination. Journal of Hazardous Materials. 242, 127706.
He, Y., Zhang, W., Ma, J., Xia, Q., Song, Z., Zhu, L., Zhang, C., Liu, J., Ye, Y., Fu, P.P., Zhuge, Y.** & Lin, G. ** (2021). Blood pyrrole-DNA adducts define the early tumorigenic risk in patients with pyrrolizidine alkaloid-induced liver injury. Environmental Science & Technology Letters. 8, 551-557.
Wu, X., Yin, C., Ma, J., Chai, S., Zhang, C., Yao, S., Kadioglu, O., Efferth, T., Ye, Y., To, K.K.** & Lin, G.** (2021). Polyoxypregnanes as safe, potent and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo. Acata Pharmaceutical Sinica B. 11, 1885-1902.
Zhu, L., Zhang, C.Y., Li, D.P., Chen, H.B., Ma, J., Gao, H. , Ye, Y., Wang, J.Y., Fu, P.P. & Lin, G.* (2021). Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacologica Sinica. 42, 1212-1222.
He, Y., Zhu, L., Ma, J., Wong, L., Zhao, Z., Ye, Y., Fu, P.P. & Lin, G. * (2020). Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. Environmental Pollution. 267, 115542.
Yang, M., Ma, J., Ruan, J.Q., Ye, Y., Fu, P.P., & Lin, G.* (2019). Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Archives of Toxicology, 93, 2197-2209.
Lu, Y., Ma, J., Song, Z., Ye, Y., Fu, P.P., & Lin, G.* (2018). The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity. Archives of Toxicology, 92, 3403-3414.
Zhu, L., Ruan, J.Q., Li, N., Fu, P.P., Ye, Y., & Lin, G.* (2016). A novel ultra-performance liquid chromatography hyphenated with quadrupole time of flight mass spectrometry method for rapid estimation of total toxic retronecine-type of pyrrolizidine alkaloids in herbs without requiring corresponding standards. Food Chemistry, 194, 1320-1328.
Yao, S., To, K.K.W., Ma, L., Yin, C., Tang, C.P., Chai, S., Ke, C.Q., Lin, G.** & Ye, Y.** (2016). Polyoxypregane steroids with open-chain sugar moiety from Marsdenia tenacissima and their chemoresistance reversal activity. Phytochemistry. 126, 47-58.
Zhu, L., Ruan, J.Q., Li, N., Fu, P.P., Ye, Y. & Lin G.* (2016). A novel ultra-performance liquid chromatography hyphenated with quadrupole time of flight mass spectrometry method for rapid estimation of total toxic retronecine-type of pyrrolizidine alkaloids in herbs without requiring corresponding standards. Food Chemistry. 194, 1320-1328.
Yang, M.B., Ruan, J.Q., Fu, P.P., & Lin, G.* (2015). Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chemico-Biological Interactions, 24, 119-126.
Zhan, S.L., Chu, Z.Q., Yin, C., Zhang, C.Y., Lin, G.*, & Li, Q.* (2013). Controllable drug release and simultaneously carrier decomposition of SiO2-drug composite nanoparticles. Journal of the American Chemical Society, 135, 5709-5716.
Chu, Z.Q., Yin, C., Zhan, S.L., Lin, G.** and Li, Q.** (2013). Surface plasmon enhanced drug efficacy using core shell Au@SiO2 nanoparticle carrier. Nanoscale. 5, 3406-3411.
Kan, W.L.T., Yin, C., Xu, H.X., Xu, G., To, K.K.W., Cho, C.H., Rudd, J.A., & Lin, G.* (2013). Anti-tumor effects of novel compound, guttiferone K, on colon cancer by p21Waf1/Cip1- mediated G0/G1 cell cycle arrest and apoptosis. International Journal of Cancer, 132, 707-716.
Ma, B., Chai, S., Li, M., To, K.K.W., Kan, W.L.T., Yang, D. & Lin, G.* (2012). Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic. International Journal of Pharmaceutics. 424, 33-39.
Ma, B., Yang, D., Li, N., & Lin, G.* (2011). Effects of structural modification on intestinal absorption and transport mechanism of α–aminoxy peptides. Molecular Pharmaceutics, 8, 1073-1082.
Lin, G.,* Wang, J.Y., Li, N., Li, M., Gao, H., Ji, Y., Zhang, F., Zhou, Y., Ye, Y., Xu, H.X., & Zheng, J. (2011). Hepatic sinusoidal obstruction syndrome associated with Gynura segetum. Journal of Hepatology, 54, 666-673.

* Corresponding / Co-corresponding author

Grants

Nine research projects supported by RGC – General Research Fund with total of HK$9,207,512
Nin Jiom Medicine Mfy. (H.K.) Ltd. [PI; 01-Nov-2017 to 31-Dec-2018]: “Evaluation of Potential Contamination of Pyrrolizidine Alkaloids in Herbal Anti-cough Syrup” (HK$50,000).
Sinoveda Canada Inc. [PI; 01-Jun-2010 to 01-Jun-2017]: “Development of Traditional Chinese Medicine (TCM)-Based Products” (HK668,123).
US Centers for Disease Control and Prevention [PI; 01-Jan-2011 to 30-Jun-2015]: “Pyrrolizidine Alkaloid-induced Liver Disease (PAILD) Outbreak, Tigray, Ethiopia: Levels of Pyrrolizidine Alkaloids (PA) Biomarkers among Members of the Affected Community” (HK$645,645).